Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FQGY8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $8,511
Award facts
- Contract value 100% obligated
- $8,510.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $8,510.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count). This firm fixed-price delivery order, issued on January 28, 2026 with an ultimate completion date of January 29, 2026, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The award was funded by the Defense Logistics Agency and performed at the contractor's Park Ridge, Illinois location.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy. The underlying IDC, designated contract SPE2DR and awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supplying pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated substantial performance across diverse therapeutic categories, including oncology treatments, immunosuppressants, biologics, and specialty pharmaceuticals, supporting recurring medical supply needs of military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQGY8?
SPE2DR26FQGY8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FQGY8 worth?
The government has obligated $8,511 on SPE2DR26FQGY8.
Is contract SPE2DR26FQGY8 an order under another contract?
Yes. SPE2DR26FQGY8 is a delivery order under SPE2DR25D9156, an indefinite delivery contract.
Was contract SPE2DR26FQGY8 competed?
The extent of competition for SPE2DR26FQGY8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award